Peter Burema, CEO of NextPharma, explains the specificities of a UK-based CDMO with manufacturing sites on the European continent. He describes how NextPharma refocused its efforts on being a customer-centric one-stop-shop by deciding on smart investments, and why quality will always remain the key differentiation factor for a CDMO.
In 2014 you joined NextPharma after a highly international career. Let’s start by introducing the company and the scope of operations of NextPharma today.
"All our sites are profitable with growing business with both existing and new customers They all offer enough space for further expansion which gives security to our customers as they don’t have to worry about limitations in servicing their future increased demand."
